The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Johnson & Johnson Innovative Medicine, said in a statement. "Spravato is now available as a standalone treatment, meaning ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...